Scarica l'app Stockscreener
23.42
2.29%
-0.55
Dopo l'orario di chiusura:
23.42
Precedente Chiudi:
$23.97
Aprire:
$23.88
Volume 24 ore:
388.07K
Relative Volume:
0.81
Capitalizzazione di mercato:
$1.39B
Reddito:
-
Utile/perdita netta:
$-85.21M
Rapporto P/E:
-12.39
EPS:
-1.89
Flusso di cassa netto:
$-68.53M
1 W Prestazione:
+13.63%
1M Prestazione:
+14.41%
6M Prestazione:
+23.65%
1 anno Prestazione:
-15.91%
Intervallo 1D:
$23.42
$24.64
Intervallo di 1 settimana:
$20.66
$24.64
Portata 52W:
$13.30
$29.79
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Confronta ELVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
23.42 | 1.42B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Goldman | Buy |
| 2024-12-13 | Iniziato | BTIG Research | Buy |
| 2024-09-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-09 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | Jefferies | Buy |
Mostra tutto
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Using data filters to optimize entry into Enliven Therapeutics Inc.2025 Volume Leaders & Growth Focused Entry Reports - newser.com
Enliven Therapeutics Inc. stock daily chart insightsJuly 2025 Technicals & Verified Momentum Stock Alerts - newser.com
Why Enliven Therapeutics Inc. stock appeals to dividend seekersMarket Trend Summary & Entry Point Confirmation Alerts - newser.com
Enliven Therapeutics Inc. recovery potential after sell offEarnings Overview Report & Weekly Watchlist of Top Performers - newser.com
Can Enliven Therapeutics Inc. stock deliver strong Q4 earningsMarket Growth Summary & Free Fast Gain Swing Trade Alerts - newser.com
Applying sector rotation models to Enliven Therapeutics Inc.2025 Market Trends & Daily Oversold Bounce Ideas - newser.com
Is Enliven Therapeutics Inc. stock a safe haven assetWeekly Earnings Recap & Fast Entry Momentum Alerts - newser.com
Is Enliven Therapeutics Inc. stock cheap compared to fundamentalsInsider Selling & Free Expert Verified Stock Movement Alerts - newser.com
Is Enliven Therapeutics Inc. stock positioned well for digital economyTrade Performance Summary & Safe Swing Trade Setups - newser.com
Automated trading signals detected on Enliven Therapeutics Inc.Portfolio Value Report & Safe Swing Trade Setups - newser.com
Real time breakdown of Enliven Therapeutics Inc. stock performanceWeekly Trade Review & Entry Point Confirmation Signals - newser.com
Is Enliven Therapeutics Inc a good long term investmentFederal Reserve Announcements & Build Wealth With Zero-Cost Tools - earlytimes.in
Will Enliven Therapeutics Inc. stock outperform tech sector in 2025Quarterly Portfolio Summary & Verified Technical Trade Signals - fcp.pa.gov.br
Will Enliven Therapeutics Inc. stock rally after Fed decisionsMarket Risk Summary & Real-Time Volume Surge Alerts - fcp.pa.gov.br
Enliven Therapeutics Advances in CML Treatment with ELVN-001 Study - TipRanks
Enliven Therapeutics’ ELVN-001: A Promising Phase 1 Study for Chronic Myeloid Leukemia - TipRanks
Enliven Therapeutics calls for advancements in CML treatments - Traders Union
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):